Neurologic disorders tied to increased risk for in-hospital mortality
Inactivated SARS-CoV-2 Vaccine Well Tolerated in Phase 1/2 Trial
Neutralizing antibody geometric mean titers higher in vaccine group at day 42 in phase 1 trial
COVID-19-Linked Deaths Mainly in Seniors in May to August 2020
Percentage of decedents who were Hispanic increased from 16.3 to 26.4 percent in May to August
No Pfizer COVID-19 Vaccine Expected Before Election
Company has reversed its previous claims that it would apply for the approval in October
Time to Results Faster With Point-of-Care COVID-19 Testing
Time to results significantly shorter with QIAstat-Dx Respiratory SARS-CoV-2 Panel than with PCR
NIH Launches Trial of Antibody Drugs Against COVID-19
The phase 2 trial will assess effectiveness of monoclonal antibodies in conjunction with remdesivir
Sitagliptin May Cut Mortality in T2DM Patients With COVID-19
Sitagliptin at time of hospitalization linked to reduced mortality, improved clinical outcomes
COVID-19 Antibody Treatment Study Paused
ACTIV-3 study, testing use of an antibody therapy with remdesivir, paused ‘out of an abundance of caution’
Symptoms of COVID-19 Poor Marker for SARS-CoV-2 Infection
Only 13.9 percent of individuals with positive test reported specific symptoms on the day of the test
Bedside Tracheotomy Feasible for Critically Ill COVID-19 Patients
No infection identified among surgeons following procedure; postoperative complications rarely seen